Avalon Pharma renews SAR 50m Alinma Bank facility as profit climbs 26%
What's the deal? Avalon PharmaDealroom has a profile for this one. Try Dealroom → renewed its Sharia-compliant banking facility agreement with Alinma BankDealroom has a profile for this one. Try Dealroom → on 19 August 2026 for SAR 50 million. The credit facility runs for one year, and the company issued a promissory note for the full amount as a guarantee.
What it means Management said the facility will fund working capital requirements and capital expenditures. Avalon Pharma confirmed that no related parties are involved.
Why now? In the first half of 2026, Avalon Pharma posted net profit of SAR 55.70 million, up 25.99% from SAR 44.21 million a year earlier.
The signal: Locking in a one-year credit line while profit grows gives the Riyadh-based drugmaker room to invest without stretching its balance sheet.
Read more: Mubasher
Image credit: Generated with Gemini
